Metro Healthcare Berhad (0329) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Metro Healthcare Berhad stock MYR 0.14, price MYR 0.22, that is 34.9% below the price, quality 57 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 0.1771 MYR – 0.6588 MYR · fair‑value band 0.1200 MYR – 0.1600 MYR · the 0.2150 MYR price screens above the 0.1400 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Metro Healthcare Berhad in your weekly email
Every Wednesday you see whether Metro Healthcare Berhad is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Metro Healthcare Berhad, together with its subsidiaries, provides hospital and related services in Malaysia.
Show moreShow less
It offers inpatient; outpatient; and ambulatory care, including in vitro fertilization (IVF), intrauterine insemination (IUI), blastocyst culture, surgical sperm retrieval, preimplantation genetic screening (PGT), and assisted hatching services.
The company also provides fertility services, such as assisted reproductive technology and specialized fertility procedures; and obstetrics services that include pre-pregnancy screening and counselling, family planning counselling, antenatal checkup, and delivery services.
In addition, it offers gynecology services, including hysterectomy, oophorectomy, colposcopy, hysteroscopy, laparoscopy, tubal ligation, dilation and curettage, and marsupialization; pediatrics services; diagnostic imaging services; and other healthcare services.
Metro Healthcare Berhad was founded in 1989 and is based in Klang, Malaysia.
Stock analysis
Metro Healthcare Berhad (0329) currently trades at 0.2150 MYR, while our model-based Fair Value estimate is 0.1400 MYR, 35% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 0.1550 MYR per share, and 2 of the 26 models we run sit above the 0.2150 MYR price.
Bear case: the Asset-Based group reads lowest at 0.0400 MYR, and 24 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 0.1200 MYR (bear) to 0.1600 MYR (bull), the price of 0.2150 MYR sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Metro Healthcare Berhad reported revenue of 50.4M MYR in FY2025 versus 42.3M MYR in FY2021, a compound +4.5%/yr. Reported net income was 5.9M MYR in FY2025, compounding −11.2%/yr from FY2021.
Key figures
Market cap 210M MYR (≈ $51.9M) Micro · P/E ratio 21.5 · P/S ratio 2.50 · EPS (TTM) 0.0100 MYR · Dividend yield 2.3% · Net margin 11.6% · Return on equity 9.2% · Return on assets (EBIT) 11.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 12% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −35%, 0329 screens richer than that median.
Fair Value models
Bear0.1200 MYRFair Value 0.1400 MYRBull0.1600 MYR
Price 0.2150 MYR · Downside -34.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0043 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.8%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−9.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.2%
Dividend (yield on the price)2.3%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 14%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Malaysia: IMF forecast 2.0% a year to 2030, 1.8% from 2016 to 2025) that is about +15.0% a year for the price.
Compare Metro Healthcare Berhad with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside−34.9% · Below median
Profitability
Return on equity (12 months)9.2% · Above median
Return on assets6.3% · Above median
Net margin (12 months)13.4% · Top 25%
Operating margin (12 months)17.3% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)4.8% · Below median
Dividend yield (12 months)2.3% · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)21.5× · Pricier than median
P/B2.80× · Pricier than median
P/S (12 months)4.12× · Priciest 25%
Price / free cash flow (fiscal year)27.7× · Pricier than median
EV/EBITDA14.3× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 34
FUTURE (revenue growth)24· sector 31
PAST (return on equity)37· sector 32
HEALTH (low debt)100· sector 90
DIVIDEND (yield)47· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Metro Healthcare Berhad (0329) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 0.1400 MYR versus a price of 0.2150 MYR, about 35% lower (overvalued).
What is the fair value of 0329?
Our model-based fair value for Metro Healthcare Berhad is 0.1400 MYR (as of Nov 9, 2026), built from audited fundamentals. The current price: 0.2150 MYR.
What is the quality score of 0329?
Metro Healthcare Berhad has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Metro Healthcare Berhad (0329)?
Our model-based price target is the fair value of 0.1400 MYR (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 0.1200 MYR, optimistic scenario 0.1600 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Metro Healthcare Berhad stock forecast for 2026?
Our models put fair value at 0.1400 MYR, about 35% lower versus a price of 0.2150 MYR (overvalued). Cautious scenario 0.1200 MYR, optimistic scenario 0.1600 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Metro Healthcare Berhad (0329)?
Metro Healthcare Berhad reported trailing-twelve-month revenue of about 51.1M MYR (latest available figure, as of Nov 9, 2026).
Does Metro Healthcare Berhad pay a dividend?
Metro Healthcare Berhad currently shows a dividend yield of 2.33% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Metro Healthcare Berhad (0329) and when is the ex-dividend date?
Metro Healthcare Berhad pays a dividend of 0.005 MYR per share a year, a dividend yield of 2.3%. The last ex-dividend date was Apr 6, 2026. A dividend has been paid every year since at least 2018. The payout ratio is 50.0% of earnings. Free cash flow covers the dividend 1.55 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Metro Healthcare Berhad (0329)?
For today's price to be fair in a discounted-cash-flow model, Metro Healthcare Berhad would have to grow free cash flow by +17.2 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +4.5 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 0329 use?
Our models discount Metro Healthcare Berhad at 12.6 %: a base by market capitalisation (micro), damped by beta 0.25, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Metro Healthcare Berhad that is +17.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Metro Healthcare Berhad (0329) delivered so far?
Over the past 4 years revenue at Metro Healthcare Berhad grew +4.5 % a year. The price currently implies free-cash-flow growth of +17.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Metro Healthcare Berhad (0329) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Metro Healthcare Berhad (+17.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Metro Healthcare Berhad (0329)?
The free-cash-flow yield on the price is 3.61 %: that much free cash flow Metro Healthcare Berhad produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Metro Healthcare Berhad (0329)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Metro Healthcare Berhad it is 0.1400 MYR per share (as of Nov 9, 2026), against a price of 0.2150 MYR. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Metro Healthcare Berhad stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 0329 trades above its calculated fair value: price 0.2150 MYR, fair value 0.1400 MYR, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0329?
No. The price is what the market pays today (0.2150 MYR); the fair value is what the company's own numbers justify (0.1400 MYR). For Metro Healthcare Berhad the two are 0.0750 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Metro Healthcare Berhad worth?
The market values Metro Healthcare Berhad at about 210M MYR (market capitalisation, as of Nov 9, 2026). Per share that is 0.2150 MYR; our models calculate a fair value of 0.1400 MYR per share.
What do the bullish and bearish scenarios say about 0329?
Our models span a range for Metro Healthcare Berhad: cautious scenario 0.1200 MYR, base 0.1400 MYR, optimistic 0.1600 MYR per share (as of Nov 9, 2026, price 0.2150 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0329?
Metro Healthcare Berhad trades at a price-to-earnings ratio of 21.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 0.1400 MYR is built from several models across several years. Other multiples: P/B 2.8, P/S 4.1, EV/EBITDA 14.3.
How solid is the balance sheet of Metro Healthcare Berhad (0329)?
Balance-sheet figures for Metro Healthcare Berhad (as of Nov 9, 2026): return on equity 9.2%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 0329 from its 52-week high?
Metro Healthcare Berhad trades at 0.2150 MYR, about 12% below its 52-week high of 0.2450 MYR and 8% above the low of 0.2000 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 0.1400 MYR is for.
Which stocks are comparable to Metro Healthcare Berhad?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Metro Healthcare Berhad stock attractive at the current price?
The data as of Nov 9, 2026: price 0.2150 MYR, calculated fair value 0.1400 MYR (−35%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0329 calculated?
We run Metro Healthcare Berhad through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 0.1400 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Metro Healthcare Berhad itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Metro Healthcare Berhad (0329)?
The closing price on Nov 6, 2026 was 0.2150 MYR. Our model-based fair value is 0.1400 MYR, about 35% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Metro Healthcare Berhad right now?
The price sits above even our optimistic bull case (0.1600 MYR). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Metro Healthcare Berhad
How large is the market capitalisation of Metro Healthcare Berhad (0329)?
The market capitalisation of Metro Healthcare Berhad is 210M MYR (≈ $51.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Metro Healthcare Berhad (0329)?
The price-to-sales ratio of Metro Healthcare Berhad is 2.50 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Metro Healthcare Berhad (0329)?
Earnings per share at Metro Healthcare Berhad are 0.0100 MYR (price ÷ EPS = P/E 21.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Metro Healthcare Berhad (0329)?
The dividend yield of Metro Healthcare Berhad is 2.3% (payout 50.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Metro Healthcare Berhad (0329)?
The net margin of Metro Healthcare Berhad is 11.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Metro Healthcare Berhad (0329)?
The return on equity (ROE) of Metro Healthcare Berhad is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Metro Healthcare Berhad (0329)?
On an EBIT basis the return on assets of Metro Healthcare Berhad is 11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Metro Healthcare Berhad (0329)?
The operating margin of Metro Healthcare Berhad is 17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Metro Healthcare Berhad (0329)?
Revenue at Metro Healthcare Berhad is growing +4.8% versus a year earlier (3y avg +7.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Metro Healthcare Berhad (0329)?
Earnings per share at Metro Healthcare Berhad are growing +25.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Metro Healthcare Berhad in the live analysis
One click puts Metro Healthcare Berhad on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026